Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2024-04-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
营业收入扣除事项的专项审核报告
Regulatory Filings
2024-04-29 Chinese
江苏四环生物股份有限公司关于2023年度计提资产减值准备及核销资产的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Jiangsu Sihuan Bio Co., Ltd. regarding the 2023 annual asset impairment provisions and asset write-offs. It includes detailed accounting policies, impairment testing methods, and the financial impact of these provisions on the company's 2023 consolidated financial statements. The document references compliance with accounting standards and includes specific figures for impairment and write-offs. However, the document length is 4174 characters, which is relatively short and the content is focused on a specific accounting event rather than a full annual or interim report. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and broader business analysis. It is also not a simple announcement of a report publication. The document is a regulatory announcement about asset impairment and write-offs, which fits best under Regulatory Filings (RNS) as it does not fit neatly into other categories like Audit Report or Earnings Release. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2024-04-29 Chinese
江苏四环生物股份有限公司关于续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the proposed reappointment of the auditing firm Zhongshen Asia Pacific Accounting Firm for the 2024 fiscal year. It details the qualifications, independence, and integrity of the audit firm and the procedures followed for the reappointment, including board and audit committee approvals. The document does not contain any actual audit report, financial statements, or detailed financial data. It is a formal announcement about the intention to renew the audit engagement, which will be submitted to the shareholders for approval. The document length is relatively short (2691 characters), and it serves as a notice rather than the audit report itself. Therefore, it fits best under the category of Audit Report / Information (AR) as it relates to audit firm appointment information but is not the full annual report or audit report itself. However, since it is an announcement about the audit firm appointment and not the audit report or results, the most appropriate classification is Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories better.
2024-04-29 Chinese
江苏四环生物股份有限公司战略发展委员会议事规则（2024年4月）
Governance Information Classification · 100% confidence The document is titled as the "Rules of Procedure for the Strategic Development Committee of the Board of Directors" of Jiangsu Sihuan Bio Co., Ltd. It details the composition, responsibilities, meeting procedures, and decision-making rules of a board committee. There is no financial data, no report of financial results, no announcement of voting results, no executive changes, no legal proceedings, no capital updates, and no earnings information. The document is a governance-related internal rules document about the board committee structure and procedures. Therefore, it fits the category of Governance Information (CGR). The document length is about 4,838 characters, which is sufficient for a detailed governance document, not a brief announcement or a report publication announcement.
2024-04-29 Chinese
2023年年度审计报告
Regulatory Filings
2024-04-29 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board meeting of Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It details the approval of the 2023 Annual Report, Supervisory Board Work Report, Financial Statements, Profit Distribution Plan, Supervisory Board remuneration, Internal Control Evaluation Report, and a proposal regarding accumulated losses. The document is a meeting resolution announcement and does not contain the full annual report or detailed financial statements itself. It references that the full reports are disclosed elsewhere (e.g., on the information disclosure platform). The document length is short (1487 characters) and primarily serves as an announcement of meeting resolutions rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution disclosure, not as the Annual Report (10-K) or Management Report (MDA).
2024-04-29 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.